Phathom Pharmaceuticals, Inc. EPS (Basic)

EPS (Basic) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Basic) growth rates and interactive chart. Basic earnings per share (EPS) tells investors how much of a firm's net income was allotted to each share of common stock. It is reported in a company's income statement and is especially informative for businesses with only common stock in their capital structures. Calculated as net income to common divided by the weighted average number of basic shares outstanding (doesn't take into account potential dilution from options or share issuance).


Highlights and Quick Summary

  • EPS (Basic) for the quarter ending June 30, 2022 was -1.33 (a 24.3% increase compared to previous quarter)
  • Year-over-year quarterly EPS (Basic) increased by 35.71%
  • Annual EPS (Basic) for 2021 was -3.89 (a 0.26% increase from previous year)
  • Annual EPS (Basic) for 2020 was -3.88 (a -62.4% decrease from previous year)
  • Annual EPS (Basic) for 2019 was -10.32 (a 20540.0% increase from previous year)
  • Twelve month EPS (Basic) ending June 30, 2022 was -4.33 (a 8.25% increase compared to previous quarter)
  • Twelve month trailing EPS (Basic) decreased by -4.2% year-over-year
Trailing EPS (Basic) for the last four month:
30 Jun '22 31 Mar '22 31 Dec '21 30 Sep '21
-4.33 -4.0 -3.89 -4.52
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Basic) of Phathom Pharmaceuticals, Inc.

Most recent EPS (Basic)of PHAT including historical data for past 10 years.

Interactive Chart of EPS (Basic) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. EPS (Basic) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -1.33 -1.07
2021 -0.95 -0.98 -1.0 -0.96 -3.89
2020 -1.58 -1.02 -0.64 -0.62 -3.88
2019 -3.96 -9.3 -10.32
2018 -0.05

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology